

Supporting Information

Alkene Oxyamination using Malonoyl Peroxides: Preparation of Pyrrolidines and Isoxazolidines

Carla Alamillo-Ferrer,[†] Jonathan M. Curle,[†] Stuart C. Davidson,[†] Simon C. C. Lucas,^{†,‡} Stephen J. Atkinson,[‡] Matthew Campbell,[‡] Alan R. Kennedy[†] and Nicholas C. O. Tomkinson^{†,*}

[†]*WestCHEM, Department of Pure and Applied Chemistry, Thomas Graham Building, University of Strathclyde, 295 Cathedral Street, Glasgow, G1 1XL, United Kingdom*

[‡]*GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom*


Nicholas.Tomkinson@strath.ac.uk

Contents

S3–S123	^1H NMR, ^{13}C NMR spectra
S124	Single crystal X-ray data for 10
S126	Single crystal X-ray data for 37
S128	Figure S3. DSC data for malonoyl peroxide 1


Malonoyl peroxide 1, ^1H NMR 500 MHz CDCl_3

^1H NMR (500 MHz, CDCl_3)




7.26


2.10




Malonoyl peroxide 1, ^{13}C NMR 126 MHz CDCl_3




2-(But-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 500 MHz CDCl_3



2-(But-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 126 MHz CDCl_3




(E)-2-(4-Phenylbut-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 500 MHz CDCl_3




(E)-2-(4-Phenylbut-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 126 MHz CDCl_3


S171647.011.esp




(E)-2-(4-*p*-Tolyl)but-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 500 MHz CDCl_3




(E)-2-(4-*p*-Tolyl)but-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 126 MHz CDCl_3




(E)-2-(4-*m*-Tolyl)but-3-en-1-ylisoindoline-1,3-dione, ^1H NMR 500 MHz CDCl_3




(E)-2-(4-*m*-Tolyl)but-3-en-1-ylisoindoline-1,3-dione, ^{13}C NMR 126 MHz CDCl_3




(E)-2-(4-*o*-Tolyl)but-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 500 MHz CDCl_3




(E)-2-(4-*o*-Tolyl)but-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 126 MHz CDCl_3




(E)-2-(4-(4-Chlorophenyl)but-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 500 MHz CDCl_3




(E)-2-(4-(4-Chlorophenyl)but-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 126 MHz CDCl_3




(E)-2-(4-(3-Chlorophenyl)but-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 500 MHz CDCl_3




(E)-2-(4-(3-Chlorophenyl)but-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 126 MHz CDCl_3




(E)-2-(4-([1,1'-Biphenyl]-4-yl)but-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 400 MHz CDCl_3




(E)-2-(4-([1,1'-Biphenyl]-4-yl)but-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 101 MHz CDCl_3




(E)-2-(4-(4-(1,3-Dioxolan-2-yl)phenyl)but-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 500 MHz CDCl_3




(E)-2-(4-(4-(1,3-Dioxolan-2-yl)phenyl)but-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 101 MHz CDCl_3



(E)-2-(4-(4-Trifluoromethyl)phenyl)but-3-en-1-yl)isoindoline-1,3-dione, ¹H NMR 500 MHz CDCl₃





(*E*)-2-(4-(4-Trifluoromethyl)phenyl)but-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 126 MHz CDCl_3




4,4-Diphenylbut-3-en-1-ol, ^1H NMR 400 MHz CDCl_3

S164620.010.esp




4,4-Diphenylbut-3-en-1-ol, ^{13}C NMR 100 MHz CDCl_3

S165227.011.esp




(4-Bromobut-1-ene-1,1diyl)dibenzene, ^1H NMR 400 MHz CDCl_3




(4-Bromobut-1-ene-1,1diyl)dibenzene, ^{13}C NMR 101 MHz CDCl_3


S165469.011.esp




2-(4,4-Diphenylbut-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 400 MHz CDCl_3




2-(4,4-Diphenylbut-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 101 MHz CDCl_3




(E)-4-Methyl-N-(4-phenylbut-3-en-1-yl)benzenesulfonamide 8a, ^1H NMR 500 MHz CDCl_3




(E)-4-Methyl-N-(4-phenylbut-3-en-1-yl)benzenesulfonamide 8a, ^{13}C NMR 126 MHz CDCl_3




(E)-4-Methyl-N-(4-(*p*-tolyl)but-3-en-1-yl)benzenesulfonamide, ¹H NMR 500 MHz CDCl₃



(E)-4-Methyl-N-(4-(*p*-tolyl)but-3-en-1-yl)benzenesulfonamide, ^{13}C NMR 126 MHz CDCl_3




(E)-4-Methyl-N-(4-(*m*-tolyl)but-3-en-1-yl)benzenesulfonamide, ^1H NMR 500 MHz CDCl_3



(E)-4-Methyl-N-(4-(*m*-tolyl)but-3-en-1-yl)benzenesulfonamide, ^{13}C NMR 126 MHz CDCl_3

^{13}C NMR (126 MHz, CDCl_3)




143.52
138.19
137.11
136.89
133.36
129.84
128.55
128.39
127.27
126.98
125.46
123.40


42.70

33.11


21.63
21.48




(E)-4-Methyl-N-(4-(*o*-tolyl)but-3-en-1-yl)benzenesulfonamide, ^1H NMR 500 MHz CDCl_3




(E)-4-Methyl-N-(4-(*o*-tolyl)but-3-en-1-yl)benzenesulfonamide, ^{13}C NMR 126 MHz CDCl_3




(E)-2-(4-([1,1'-Biphenyl]-4-yl)but-3-en-1-yl)-4-methylbenzenesulfonamide, ^1H NMR 500 MHz CDCl_3




(E)-2-(4-([1,1'-Biphenyl]-4-yl)but-3-en-1-yl)-4-methylbenzenesulfonamide, ^{13}C NMR 126 MHz CDCl_3




(E)-N-(4-(4-Chlorophenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide, ^1H NMR 500 MHz CDCl_3




(E)-N-(4-(4-Chlorophenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide, ^{13}C NMR 126 MHz CDCl_3




(E)-N-(4-(3-Chlorophenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide, ^1H NMR 500 MHz CDCl_3




(E)-N-(4-(3-Chlorophenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide, ^{13}C NMR 126 MHz CDCl_3




(E)-N-(4-(4-(1,3-Dioxolan-2-yl)phenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide, ^1H NMR 400 MHz CDCl_3




(E)-N-(4-(4-(1,3-Dioxolan-2-yl)phenyl)but-3-en-1-yl)-4-methylbenzenesulfonamide, ^{13}C NMR 101 MHz CDCl_3




(E)-4-Methyl-N-(4-(4-(trifluoromethyl)phenyl)but-3-en-1-yl)benzenesulfonamide, ^1H NMR 500 MHz CDCl_3




(E)-4-Methyl-N-(4-(4-(trifluoromethyl)phenyl)but-3-en-1-yl)benzenesulfonamide, ^{13}C NMR 126 MHz CDCl_3




***N*-(4,4-Diphenylbut-3-en-1-yl)-4-methylbenzenesulfonamide, ^1H NMR 400 MHz CDCl_3**




***N*-(4,4-Diphenylbut-3-en-1-yl)-4-methylbenzenesulfonamide, ^{13}C NMR 101 MHz CDCl_3**




(E)-(4-phenylbut-3-en-1-yl)acetamide 8b, ^1H NMR 400 MHz CDCl_3




(E)-(4-phenylbut-3-en-1-yl)acetamide 8b, ^{13}C NMR 101 MHz CDCl_3



***tert*-Butyl (*E*)-(4-phenylbut-3-en-1-yl)carbamate 8c, ^1H NMR 400 MHz CDCl_3**




***tert*-Butyl (*E*)-(4-phenylbut-3-en-1-yl)carbamate 8c, ^{13}C NMR 101 MHz CDCl_3**




Benzyl (*E*)-(4-phenylbut-3-en-1-yl)carbamate 8d, ^1H NMR 400 MHz CDCl_3

S171276.010.esp




Benzyl (*E*)-(4-phenylbut-3-en-1-yl)carbamate 8d, ^{13}C NMR 101 MHz CDCl_3

S171276.011.esp




(E)-2,4-Dinitro-N-(4-phenylbut-3-en-1-yl)benzenesulfonamide 8e, ^1H NMR 400 MHz CDCl_3



S171802.010.esp




(E)-2,4-Dinitro-N-(4-phenylbut-3-en-1-yl)benzenesulfonamide 8e, ^{13}C NMR 101 MHz CDCl_3

S171802.011.esp




¹H NMR (400 MHz, CDCl₃)


(±)-2-Phenyl-1-tosylpyrrolidin-3-ol 9a, purified sample ^1H NMR 500 MHz CDCl_3




(±)-2-Phenyl-1-tosylpyrrolidin-3-ol 9a, purified sample ^{13}C NMR 126 MHz CDCl_3




(±)-2-(*p*-Tolyl)-1-tosylpyrrolidin-3-ol 13, crude reaction mixture ^1H NMR 400 MHz CDCl_3




(±)-2-(*p*-Tolyl)-1-tosylpyrrolidin-3-ol 13, purified sample ^1H NMR 400 MHz CDCl_3




(±)-2-(*p*-Tolyl)-1-tosylpyrrolidin-3-ol 13, purified sample ^{13}C NMR 101 MHz CDCl_3




(±)-2-(*m*-Tolyl)-1-tosylpyrrolidin-3-ol 14, crude reaction mixture ^1H NMR 400 MHz CDCl_3




(±)-2-(*m*-Tolyl)-1-tosylpyrrolidin-3-ol 14, purified sample ^1H NMR 400 MHz CDCl_3




(±)-2-(*m*-Tolyl)-1-tosylpyrrolidin-3-ol 14, purified sample ^{13}C NMR 101 MHz CDCl_3




(±)-2-(*o*-Tolyl)-1-tosylpyrrolidin-3-ol 15, crude reaction mixture ¹H NMR 500 MHz CDCl₃ diastereomeric ratio not assigned.




(±)-2-(*o*-Tolyl)-1-tosylpyrrolidin-3-ol 15, purified sample ^1H NMR 400 MHz CDCl_3




(±)-2-(*o*-Tolyl)-1-tosylpyrrolidin-3-ol 15, purified sample ^{13}C NMR 101 MHz CDCl_3




(±)-2-([1,1'-Biphenyl]-4-yl)-1-tosylpyrrolidin-3-ol 16, crude reaction mixture ^1H NMR 500 MHz CDCl_3




(±)-2-([1,1'-Biphenyl]-4-yl)-1-tosylpyrrolidin-3-ol 16, purified sample ^1H NMR 500 MHz CDCl_3




(±)-2-([1,1'-Biphenyl]-4-yl)-1-tosylpyrrolidin-3-ol 16, purified sample ¹³C NMR 126 MHz CDCl₃




(±)-2-(4-Chlorophenyl)-1-tosylpyrrolidin-3-ol 17, crude reaction mixture ^1H NMR 400 MHz CDCl_3




(±)-2-(4-Chlorophenyl)-1-tosylpyrrolidin-3-ol 17, purified sample ^1H NMR 500 MHz CDCl_3




(±)-2-(4-Chlorophenyl)-1-tosylpyrrolidin-3-ol 17, purified sample ^{13}C NMR 126 MHz CDCl_3




(±)-2-(3-Chlorophenyl)-1-tosylpyrrolidin-3-ol 18, crude reaction mixture ^1H NMR 400 MHz CDCl_3




(±)-2-(3-Chlorophenyl)-1-tosylpyrrolidin-3-ol 18, purified sample ^1H NMR 500 MHz CDCl_3




(±)-2-(3-Chlorophenyl)-1-tosylpyrrolidin-3-ol 18, purified sample ^{13}C NMR 126 MHz CDCl_3




(±)-2-(4-(1,3-Dioxolan-2-yl)phenyl)-1-tosylpyrrolidin-3-ol 19, crude reaction mixture ^1H NMR 500 MHz CDCl_3




(±)-2-(4-(1,3-Dioxolan-2-yl)phenyl)-1-tosylpyrrolidin-3-ol 19, purified sample ^1H NMR 400 MHz CDCl_3




(±)-2-(4-(1,3-Dioxolan-2-yl)phenyl)-1-tosylpyrrolidin-3-ol 19, purified sample ^{13}C NMR 101 MHz CDCl_3




(±)-(2*R*,3*S*)-1-Tosyl-2-(4-(trifluoromethyl)phenyl)pyrrolidine-3-ol 20, crude reaction mixture ¹H NMR 400 MHz CDCl₃ diastereomeric ratio not assigned.




(±)-1-Tosyl-2-(4-(trifluoromethyl)phenyl)pyrrolidine-3-ol 20, purified sample ^1H NMR 500 MHz CDCl_3




(±)-1-Tosyl-2-(4-(trifluoromethyl)phenyl)pyrrolidine-3-ol 20, purified sample ^{13}C NMR 126 MHz CDCl_3




(±)-2,2-Diphenyl-1-tosylpyrrolidin-3-ol 21, purified sample ^1H NMR 400 MHz CDCl_3




(±)-2,2-Diphenyl-1-tosylpyrrolidin-3-ol 21, purified sample ^{13}C NMR 101 MHz CDCl_3




(±)-2-Phenyl-1-tosylpyrrolidin-3-ol (22) crude reaction mixture ^1H NMR 400 MHz CDCl_3



(±)-2-Phenyl-1-tosylpyrrolidin-3-ol (22) purified material ^1H NMR 400 MHz CDCl_3




(±)-2-Phenyl-1-tosylpyrrolidin-3-ol (22) purified material ^{13}C NMR 101 MHz CDCl_3





2-(3-Bromo-4,4-diphenylbut-3-en-1-yl)isoindoline-1,3-dione, ^1H NMR 400 MHz CDCl_3

S164806.010.esp





2-(3-Bromo-4,4-diphenylbut-3-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 101 MHz CDCl_3

S164806.011.esp




2-(3-(Diphenylmethylene)pent-4-en-1-yl)isoindoline-1,3-dione, ¹H NMR 400 MHz CDCl₃

S164807.010.esp




2-(3-(Diphenylmethylene)pent-4-en-1-yl)isoindoline-1,3-dione, ^{13}C NMR 101 MHz CDCl_3

S164807.011.esp





2-(3-(Diphenylmethylene)-5-hydroxypentyl)isoindoline-1,3-dione, ^1H NMR 400 MHz CDCl_3

S164817.010.esp





2-(3-(Diphenylmethylene)-5-hydroxypentyl)isoindoline-1,3-dione, ^{13}C NMR 101 MHz CDCl_3

S164817.011.esp





***N*-(3-(Diphenylmethylene)-5-hydroxypentyl)-4-methylbenzenesulfonamide 28, ^1H NMR 600 MHz CDCl_3**

S164962.010.esp





***N*-(3-(Diphenylmethylene)-5-hydroxypentyl)-4-methylbenzenesulfonamide 28, ^{13}C NMR 157 MHz CDCl_3**

S164962.011.esp




R50533.010.esp




1-Methyl 1-(3-(2-((4-methylphenyl)sulfonamido)ethyl)-2,2-diphenyltetrahydrofuran-3-yl) cyclopropane-1,1-dicarboxylate 29, ^{13}C NMR 157 MHz CDCl_3

R50533.011.esp




Methyl 1-(5-(2-((4-methylphenyl)sulphonamide)ethyl)-6,6-diphenyl-2,7,8-trioxabicyclo[3.2.1]octan-1-yl)cyclopropane-1-carboxylate 31, ^1H NMR 600 MHz CDCl_3

R50532.010.esp




Methyl 1-(5-(2-((4-methylphenyl)sulphonamide)ethyl)-6,6-diphenyl-2,7,8-trioxabicyclo[3.2.1]octan-1-yl)cyclopropane-1-carboxylate 31, ^{13}C NMR 157 MHz CDCl_3


R50532.011.esp




Data confirmation of furan compound 29. HSQC



2-(Cinnamyloxy)isoindoline-1,3-dione, ^1H NMR 500 MHz CDCl_3




2-(Cinnamyloxy)isoindoline-1,3-dione, ^{13}C NMR 126 MHz CDCl_3




(E)-2-((3-(4-Chlorophenyl)allyl)oxy)isoindoline-1,3-dione, ^1H NMR 400 MHz CDCl_3

S171839.010.esp




(E)-2-((3-(4-Chlorophenyl)allyl)oxy)isoindoline-1,3-dione, ^{13}C NMR 101 MHz CDCl_3

S171848.011.esp




***N*-(Cinnamyloxy)-4-methylbenzenesulfonamide 33, ^1H NMR 500 MHz CDCl_3**



***N*-(Cinnamyloxy)-4-methylbenzenesulfonamide 33, ^{13}C NMR 126 MHz CDCl_3**


^{13}C NMR (126 MHz, CDCl_3)



145.10
136.31
135.99
133.81
129.91
128.77
128.75
128.37
126.86
122.93


78.05

21.82





(E)-N-((3-(4-Chlorophenyl)allyl)oxy)-4-methylbenzenesulfonamide 35, ^1H NMR 500 MHz CDCl_3

S171523.010.esp




(E)-N-((3-(4-Chlorophenyl)allyl)oxy)-4-methylbenzenesulfonamide 35, ^{13}C NMR 126 MHz CDCl_3


S171523.011.esp




(±)-1-(((3-Phenyl-2-tosyloxazolidin-4-yl)oxy)carbonyl)cyclopropane-1-carboxylic acid **37**, crude reaction mixture ^1H NMR 500 MHz CDCl_3




(±)-1-(((3-Phenyl-2-tosyloxazolidin-4-yl)oxy)carbonyl)cyclopropane-1-carboxylic acid 37, purified sample ^1H NMR 400 MHz CDCl_3




(±)-1-(((3-Phenyl-2-tosyloxazolidin-4-yl)oxy)carbonyl)cyclopropane-1-carboxylic acid 37, purified sample ^{13}C NMR 101 MHz CDCl_3




(±)-1-Methyl 1-(3-phenyl-2-tosylisoxazolidin-4-yl) cyclopropane-1,1-dicarboxylate 34, crude reaction mixture ^1H NMR 400 MHz CDCl_3




(±)-1-Methyl 1-(3-phenyl-2-tosylisoxazolidin-4-yl) cyclopropane-1,1-dicarboxylate 34, purified sample ^1H NMR 500 MHz CDCl_3




(±)-1-Methyl 1-(3-phenyl-2-tosyloxazolidin-4-yl) cyclopropane-1,1-dicarboxylate 34, purified sample ^{13}C NMR 126 MHz CDCl_3




(±)-1-(3-(4-Chlorophenyl)-2-tosyloxazolidin-4-yl) 1-methylcyclopropane-1,1-dicarboxylate 36, crude reaction mixture ^1H NMR 500 MHz CDCl_3




(±)-1-(3-(4-Chlorophenyl)-2-tosyloxazolidin-4-yl) 1-methylcyclopropane-1,1-dicarboxylate 36, purified sample ^1H NMR 500 MHz CDCl_3




(±)-1-(3-(4-Chlorophenyl)-2-tosyloxazolidin-4-yl) 1-methylcyclopropane-1,1-dicarboxylate 36, purified sample ^{13}C NMR 126 MHz CDCl_3




(±)-2-Phenyl-1-tosylpyrrolidin-3-one 38, ¹H NMR 500 MHz CDCl₃



(±)-2-Phenyl-1-tosylpyrrolidin-3-one **38**, ^{13}C NMR 126 MHz CDCl_3



(±)-2-Phenyl-1-tosylpyrrolidin-3-ol 22, Dibal-H reduction crude reaction mixture ^1H NMR 500 MHz CDCl_3



X-Ray data for (±)-1-(((3-Phenyl-2-tosylisoxazolidin-4-yl)oxy)carbonyl)cyclopropane-1-carboxylic acid **10**

CCDC 1569729

Table S1. Crystal data and structure refinement for **10**.

Identification code	tom_stuart_needles
Empirical formula	C ₂₄ H ₂₇ N O ₈ S
Formula weight	489.52
Temperature	123(2) K
Wavelength	0.71073 Å
Crystal system	Monoclinic
Space group	P 2 ₁ /n
Unit cell dimensions	a = 14.2564(10) Å b = 7.5171(5) Å c = 21.4885(16) Å
Volume	2301.1(3) Å ³
Z	4
Density (calculated)	1.413 Mg/m ³
Absorption coefficient	0.192 mm ⁻¹
F(000)	1032
Crystal size	0.33 x 0.16 x 0.05 mm ³
Theta range for data collection	3.234 to 27.995°.
Index ranges	-18<=h<=17, -9<=k<=9, -27<=l<=27
Reflections collected	15728
Independent reflections	5410 [R(int) = 0.0285]
Completeness to theta = 27.000°	99.8 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	1.00000 and 0.86786
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	5410 / 0 / 315
Goodness-of-fit on F ²	1.110
Final R indices [I>2sigma(I)]	R1 = 0.0541, wR2 = 0.1081
R indices (all data)	R1 = 0.0691, wR2 = 0.1166
Extinction coefficient	n/a
Largest diff. peak and hole	0.429 and -0.441 e.Å ⁻³





Figure S1. Molecular structure of compound ($\pm$)-1-(((3-Phenyl-2-tosyloxazolidin-4-yl)oxy)carbonyl)cyclopropane-1-carboxylic acid acetic acid salt 10·AcOH. Non-H atoms have been drawn with 50 % probability ellipsoids. H atoms are drawn as small spheres of arbitrary size.



X-Ray data for (±)-1-(((3-Phenyl-2-tosylisoxazolidin-4-yl)oxy)carbonyl)cyclopropane-1-carboxylic acid 37

CCDC 1569728

Table S2. Crystal data and structure refinement for **37**.

Identification code	ferrer_caf652	
Empirical formula	C ₂₁ H ₂₁ N O ₇ S	
Formula weight	431.45	
Temperature	123(2) K	
Wavelength	1.54180 Å	
Crystal system	Monoclinic	
Space group	P2 ₁ /c	
Unit cell dimensions	a = 16.6619(6) Å	α = 90°.
	b = 10.7864(3) Å	β = 101.846(3)°.
	c = 11.6368(3) Å	γ = 90°.
Volume	2046.85(11) Å ³	
Z	4	
Density (calculated)	1.400 Mg/m ³	
Absorption coefficient	1.793 mm ⁻¹	
F(000)	904	
Crystal size	0.18 x 0.14 x 0.04 mm ³	
Theta range for data collection	4.92 to 73.18°.	
Index ranges	-20 ≤ h ≤ 20, -12 ≤ k ≤ 13, -14 ≤ l ≤ 14	
Reflections collected	18649	
Independent reflections	4075 [R(int) = 0.0344]	
Completeness to theta = 70.00°	99.8 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	1.00000 and 0.74640	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	4075 / 0 / 276	
Goodness-of-fit on F ²	1.036	
Final R indices [I > 2σ(I)]	R1 = 0.0456, wR2 = 0.1218	
R indices (all data)	R1 = 0.0534, wR2 = 0.1296	
Largest diff. peak and hole	0.412 and -0.250 e.Å ⁻³	




Figure S2. Molecular structure of compound ($\pm$)-1-(((3-Phenyl-2-tosyloxazolidin-4-yl)oxy)carbonyl)cyclopropane-1-carboxylic acid **37**. Non-H atoms have been drawn with 50 % probability ellipsoids. H atoms are drawn as small spheres of arbitrary size.





Figure S3. DSC data for malonoyl peroxide **1**.



DSC data showing melting point of malonoyl peroxide **1** at 89.8 $^{\circ}\text{C}$ and decomposition of peroxide at 181.57 $^{\circ}\text{C}$.